Search PubMed⌕ Search

Biomedical subjects

E Watanabe

Publications and source records attributed to E Watanabe.

At least 199 records · Page 11Linked to original sources
PubMed1981

Induction of tumor resistance by hybrid cell lines between human acute lymphocytic leukemia cells and mouse myeloma cells.

Three hybrid cell lines were derived from the fusion of BALB/c mouse NS-1 myeloma cells and human acute lymphocytic leukemia cells. Hybrid clones contained almost all of the mouse chromosomes and a few human chromosomes, and induced tumors in BALB/c and BALB/c nu/nu mice when inoculated subcutaneously. However, the tumors of BALB/c mice subsided spontaneously within one month. The mice which survived the inoculation of 5 approximately 10 X 10(6) hybrid cells were able to reject a subsequent challenge with 5 X 10(6) NS-1 cells. Spleen cells or lymph node cells from immune mice were injected into BALB/c mice. These mice lived longer than the mice which received normal spleen cells or normal lymph node cells, when challenged with 5 X 10(6) NS-1 cells. These results suggest that a rearrangement of tumor-specific antigens on human/mouse hybrid cells can induce immunogenicity.

Animals↗
PubMed1980

Long-term survival in acute leukemia in Japan. A study of 304 cases.

In a national survey of five-year survivors with acute leukemia, 233 of 304 cases were children under 14 years of age and 71 were adults. There were 107 myeloblastic, 10 promyelocytic, 142 lymphocytic, and 37 undifferentiated leukemias, Forty-five cases at age 3 represented the peak. These long-term survivors have shown a yearly increase in number. In 1972, the number of childhood ALL cases reached 38 with no great changes in ANLL cases. With respect to prognosis among long-term survivors, it seemed that neither type of leukemia nor age at diagnosis were factors influencing the future survival. CNS relapse occurring before the third year was an unfavorable complication for a prognosis beyond five years. Only 8 patients died of leukemia among 155 patients who reached five years in their initial complete remission; 49 of 90 patients who had relapse within five years after diagnosis died of leukemia. From these findings, it seems very important to follow patients for five years in their initial complete remission.

Adolescent↗
PubMed1979

Common leukemia-associated antigen of DBA/2 mouse leukemia detected by tumor rejection and complement-dependent cytotoxicity assays.

A cytotoxic antibody for L1210 leukemia cells was found in the (C57BL/6 x DBA/2)F1 (BDF1) mice immunized with L1210 leukemia cells infected with ts mutant of HVJ (HVJ-pi) and challenged several times with uninfected L1210 leukemia cells. These immune mice fell into two categories; high and low responders regarding the titer of cytotoxic antibody produced. The antigen defined by this cytotoxic antibody was present on leukemia cells originating in DBA/2 mice but not on leukemia induced by passage-A Gross virus or spontaneous mammary tumors. This serological cross-reactivity among L1210, P388, and L5178Y leukemia cells has been substantially confirmed by the observation of cross protection against challenge with DBA/2 leukemia cells in immune BDF1 mice. These findings strongly suggested the presence of a common DBA/2 leukemia-associated antigen different from known cell-surface antigens of murine leukemia. The results obtained in the present work also demonstrated the great efficacy of non-cytopathic, viable HVJ-pi-injected tumor cells as an immunogen for inducing tumor immunity.

Animals↗